Literature DB >> 14616887

Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.

Pedro Iglesias1, Pilar Alvarez Fidalgo, Rosa Codoceo, Juan J Díez.   

Abstract

OBJECTIVE: Adipose tissue is a hormonally active system that produces and releases different bioactive substances. Leptin, adiponectin and resistin are some of the recently discovered adipocytokines that participate in the regulation of intermediate metabolism. The aim of this study was to evaluate the circulating levels of leptin, adiponectin and resistin in patients with thyroid dysfunction before and after normalization of thyroid function with appropriate therapy. PATIENTS AND MEASUREMENTS: We studied 20 patients with hyperthyroidism (16 women and 4 men; mean age 47.2 +/- 3.9 years) and 20 patients with hypothyroidism (17 women and 3 men; 51.5 +/- 4.1 years). A group of 20 euthyroid subjects served as control group. Patients were evaluated at the time of diagnosis and again after normalization of thyroid function with appropriate therapy. Serum concentrations of free T4 (FT4), total T3, TSH, insulin, leptin, adiponectin and resistin were measured in all subjects.
RESULTS: Hyperthyroid patients showed significantly decreased leptin levels in comparison with controls (11.0 +/- 1.1 vs. 30.4 +/- 5.0 microg/l, P < 0.001). No significant differences in adiponectin levels between hyperthyroid and control groups were found (27.8 +/- 4.0 vs. 46.0 +/- 12.0 mg/l, NS). Patients with hyperthyroidism exhibited reduced resistin levels in comparison with euthyroid subjects (6.4 +/- 0.8 vs. 8.4 +/- 0.7 microg/l, P < 0.05). Normalization of circulating thyroid hormone was accompanied by a nonsignificant increase in leptin levels (12.9 +/- 1.7 microg/l, P < 0.01 vs. control) and no significant modification both in adiponectin (32.0 +/- 7.1 mg/l, NS) and resistin (5.4 +/- 0.7 microg/l, NS) levels. Adjustment of adipocytokine concentrations for body mass index (BMI) showed that treatment of hyperthyroidism induced a significant reduction in adjusted resistin concentrations (0.21 +/- 0.03 vs. 0.28 +/- 0.03 microg/l/BMI units, P < 0.05), with no changes in adjusted leptin and adiponectin. Hypothyroid patients showed significantly lower leptin levels compared with the controls (16.0 +/- 3.5 vs. 30.4 +/- 5.0 microg/l, P < 0.05). Adiponectin levels in patients with hypothyroidism (71.8 +/- 16.0 mg/l) were similar to those in the control group and were not modified with therapy. Resistin levels were significantly reduced among hypothyroid patients (5.8 +/- 1.0 microg/l, P < 0.05), and were not increased after levothyroxine therapy. A significant rise in BMI-corrected leptin levels was observed after replacement therapy, with no changes in adiponectin- and resistin-corrected values.
CONCLUSIONS: The results suggest that (1) low serum leptin levels are present in both hyperthyroid and hypothyroid patients but are only increased after therapy in the latter; (2) resistin might be implicated in the insulin resistance state that accompanies thyrotoxicosis; and (3) inadequate secretion of adiponectin seems to have no role in metabolic changes associated with thyroid dysfunction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616887     DOI: 10.1046/j.1365-2265.2003.01897.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  43 in total

1.  Plasma levels of resistin-like molecule beta in humans.

Authors:  Andrew P Neilson; Zora Djuric; Susan Land; Ikuko Kato
Journal:  Cancer Epidemiol       Date:  2010-11-19       Impact factor: 2.984

2.  Changes in the before and after thyroxine treatment levels of adipose tissue, leptin, and resistin in subclinical hypothyroid patients.

Authors:  Gulhan Akbaba; Dilek Berker; Serhat Isık; Mazhar Muslum Tuna; Suha Koparal; Murat Vural; Fatma Meric Yılmaz; Canan Topcuoglu; Serdar Guler
Journal:  Wien Klin Wochenschr       Date:  2015-09-22       Impact factor: 1.704

3.  Serum apelin levels in patients with thyroid dysfunction.

Authors:  Ali Gürel; Akif Doğantekin; Yusuf Özkan; Süleyman Aydın
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Regulation of adiponectin gene expression in adipose tissue by thyroid hormones.

Authors:  Samira Seifi; Mohammad Reza Tabandeh; Saed Nazifi; Mehdi Saeb; Sadegh Shirian; Parisa Sarkoohi
Journal:  J Physiol Biochem       Date:  2011-11-30       Impact factor: 4.158

5.  Hypothyroidism in rats decreases peripheral glucose utilisation, a defect partially corrected by central leptin infusion.

Authors:  P Cettour-Rose; C Theander-Carrillo; C Asensio; M Klein; T J Visser; A G Burger; C A Meier; F Rohner-Jeanrenaud
Journal:  Diabetologia       Date:  2005-03-09       Impact factor: 10.122

6.  Hunger-satiety signals in patients with Graves' thyrotoxicosis before, during, and after long-term pharmacological treatment.

Authors:  Sven Röjdmark; Jan Calissendorff; Olle Danielsson; Kerstin Brismar
Journal:  Endocrine       Date:  2005-06       Impact factor: 3.633

7.  Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients.

Authors:  L Sieminska; D Niedziolka; A Pillich; B Kos-Kudla; B Marek; M Nowak; H Borgiel-Marek
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

8.  Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.

Authors:  M Ozkaya; M Sahin; E Cakal; F Yuzbasioglu; K Sezer; M Kilinc; S Simsek Imrek
Journal:  J Endocrinol Invest       Date:  2009-05-15       Impact factor: 4.256

9.  AdipoR1 and AdipoR2 gene expression are regulated by thyroid hormones in adipose tissue.

Authors:  Samira Seifi; Saeed Nazifi; Mohammad Reza Tabandeh; Mehdi Saeb
Journal:  Mol Cell Biochem       Date:  2013-02-03       Impact factor: 3.396

10.  Absence of thyrotropin-induced increase in leptin levels in patients with history of differentiated thyroid carcinoma undergoing recombinant human thyrotropin testing.

Authors:  F Cecoli; G Andraghetti; C Ghiara; L Briatore; D Cavallero; M Mussap; F Minuto; M Giusti
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.